Johnson & Johnson (JNJ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 10:40 AM ESTCompany ParticipantsCandice Long - Worldwide ...
The FDA has cleared BrainsWay’s Deep Transcranial Magnetic Stimulation system for use as an adjunct therapy in adolescents with major depressive disorder.
The EMA initially rejected Rezurock due to uncertainty over its clinical benefit, noting that the pivotal study had no comparator arm and permitted concomitant therapies.
Jointly released last month in Rotterdam by the American Heart Association and American Academy of Pediatrics, these ...
Spine surgeons at Hospital for Special Surgery (HSS) reported promising findings for adolescent athletes suffering from pars ...
Southern Utah has become the backdrop for a new Hollywood film, which brings major stars to the region to tell a story rooted ...
As political attacks on gender-affirming care escalate, parents and experts fear a resurgence of discredited "therapies" that ...
The United States on Friday said it would add its most serious warning label to a gene therapy treatment for a debilitating ...
Neuro Wellness Spa -- a leader in compassionate, evidence-based mental health care -- announced the opening of its newest clinic in Lake Forest, California. This marks the 12th location in Southern ...
Adolescents who achieved a BMI reduction of at least 10% at 26 weeks with a reduced-calorie diet had significant decreases in ...
BrainsWay announced today that the FDA granted a label expansion for its deep transcranial magnetic stimulation (Deep TMS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback